AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3282026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder)
Number of subjects: 787
Study 31964674 — intervention group
Group type: EXPERIMENTAL
Intervention: Working over 55 hours per week
Number of subjects: 2706
Study 31964674 — intervention group
Group type: COMPARATOR
Intervention: Working 40-44 hours per week
Number of subjects: 2706
Study 30501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 0.1 mg/kg dexamethasone
Number of subjects: 50
Study 30501611 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (control)
Number of subjects: 50
Study 27581475 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium diet (HKD)
Number of subjects: 20
Study 27581475 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 20
Study 24127818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Number of subjects: 4844
Study 24127818 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 4844
Study 24127818 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride monotherapy
Number of subjects: 4844
Study 23234237 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention for GPs on performing a narrative doctor-patient dialogue and medication review.
Number of subjects: 0
Study 23234237 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 0
Study 20522354 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol and remifentanil
Number of subjects: 46
Study 20522354 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 46
Study 20522354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 18931605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutramigen AA
Number of subjects: 0
Study 18931605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Neocate)
Number of subjects: 0
Study 18931605 — intervention group
Group type: COMPARATOR
Intervention: Nutramigen LIPIL
Number of subjects: 0
Study 16705491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for 4 hours/week for two weeks after standard job search assistance for two weeks
Number of subjects: 0
Study 16705491 — intervention group
Group type: COMPARATOR
Intervention: Standard job search assistance for 4 hours/week for four weeks
Number of subjects: 0
Study 14617595 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil with morphine
Number of subjects: 91
Study 14617595 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 91
Study 10719942 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb), 250-ml infusions, up to three infusions
Number of subjects: 209
Study 10719942 — intervention group
Group type: COMPARATOR
Intervention: Packed erythrocytes (pRBCs), three units
Number of subjects: 209
Study 10719942 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 209
Study 10719942 — intervention group
Group type: COMPARATOR
Intervention: Control (pRBCs)
Number of subjects: 209
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin 0.3 mg/kg i.v. injection
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin 0.01 mg/kg/h continuous i.v. infusion
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin 0.02 mg/kg/h continuous i.v. infusion
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin 0.05 to 0.6 mg/kg subcutaneous doses
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin 0.2 to 0.4 mg/kg once daily subcutaneous for five days
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin 0.3 mg/kg i.v. bolus followed by daily s.c. injections
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: APTT reagents tested (BioMérieux Silimat and IL-ellagic acid)
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin
Number of subjects: 75
Study 9184402 — intervention group
Group type: COMPARATOR
Intervention: PEG-Hirudin compared to non-conjugated r-hirudin
Number of subjects: 75
Study 8264145 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day, increasing to 20 to 40 mg/day as required)
Number of subjects: 30
Study 8264145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3987180 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nifedipine infusion (4.5 mg in 45 minutes)
Number of subjects: 20
Study 3987180 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg sustained-release tablet)
Number of subjects: 20
Study 29530513 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nails (R-IMN)
Number of subjects: 60
Study 29530513 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO)
Number of subjects: 60
Study 26460743 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded 1P implants
Number of subjects: 33
Study 26460743 — intervention group
Group type: COMPARATOR
Intervention: Delayed loaded 1P implants
Number of subjects: 33
Study 26460743 — intervention group
Group type: COMPARATOR
Intervention: 2P implants
Number of subjects: 33
Study 26460743 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 33
Study 24824661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium, 300 mg twice daily
Number of subjects: 80
Study 24824661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22864465 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (5 g/day)
Number of subjects: 52
Study 22864465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20121745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin + standard-exposure tacrolimus (SET)
Number of subjects: 216
Study 20121745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin + reduced-exposure tacrolimus (RET)
Number of subjects: 216
Study 20121745 — intervention group
Group type: COMPARATOR
Intervention: Control (SET + mycophenolic acid [MPA])
Number of subjects: 216
Study 17868655 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 13
Study 17868655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16312177 — intervention group
Group type: EXPERIMENTAL
Intervention: FCT SQV (two 500 mg tablets)
Number of subjects: 100
Study 16312177 — intervention group
Group type: COMPARATOR
Intervention: HC SQV (five 200 mg capsules)
Number of subjects: 100
Study 12732885 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose (SD) CSA
Number of subjects: 100
Study 12732885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (LD) CSA
Number of subjects: 100
Study 12732885 — intervention group
Group type: COMPARATOR
Intervention: No CSA
Number of subjects: 100
Study 12732885 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA (both SD and LD)
Number of subjects: 100
Study 10469776 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-microg salmeterol powder via Diskhaler
Number of subjects: 24
Study 10469776 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-microg salmeterol powder via Diskus
Number of subjects: 24
Study 10469776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8733205 — intervention group
Group type: EXPERIMENTAL
Intervention: High treatment specificity and high delta sleep ratio
Number of subjects: 0
Study 8733205 — intervention group
Group type: EXPERIMENTAL
Intervention: High treatment specificity and low delta ratio
Number of subjects: 0
Study 8733205 — intervention group
Group type: COMPARATOR
Intervention: Low treatment specificity and low delta ratio
Number of subjects: 0
Study 1905629 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose stimulation
Number of subjects: 8
Study 1905629 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion (15 mg kg-1 min-1) during hyperglycaemic clamps
Number of subjects: 8
Study 6679363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate for hookworm
Number of subjects: 150
Study 6679363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis for malaria
Number of subjects: 150
Study 6679363 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate for S. haematobium
Number of subjects: 150
Study 6679363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31562751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 100
Study 31562751 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 100
Study 29105841 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1001
Study 29105841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1001
Study 26434752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist involvement (face-to-face medication reconciliation, patient-specific pharmaceutical care plan, discharge counseling, postdischarge phone calls on days 3, 14, and 30)
Number of subjects: 278
Study 26434752 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital standard of care (control group)
Number of subjects: 278
Study 26434752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist involvement
Number of subjects: 278
Study 24618831 — intervention group
Group type: COMPARATOR
Intervention: Community action interventions including community engagement, general practitioner training in alcohol screening and brief intervention, media campaign, and others implemented from 2005 to 2009.
Number of subjects: 20
Study 22581199 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting Resolute stent
Number of subjects: 1709
Study 22581199 — intervention group
Group type: COMPARATOR
Intervention: Everolimus‐eluting XIENCE V stent
Number of subjects: 1709
Study 20370970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring and/or exposure therapy
Number of subjects: 77
Study 20370970 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 77
Study 17395868 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous zoledronate (n=14)
Number of subjects: 27
Study 17395868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 27
Study 14961215 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CEE (1.25 mg/day)
Number of subjects: 88
Study 14961215 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CEE (0.625 mg/day)
Number of subjects: 88
Study 12244081 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 12244081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 12244081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DMO)
Number of subjects: 0
Study 12244081 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study 9690572 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg)
Number of subjects: 6
Study 9690572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7862229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin at a dose of 0.5 mg/kg (50 U1 Anti‐Xa/kg)
Number of subjects: 72
Study 7862229 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased doses of enoxaparin between 0.6 and 0.9 mg/kg as needed
Number of subjects: 72
Study 7862229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dose of enoxaparin at the end of the study
Number of subjects: 72
Study 7862229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin treatment
Number of subjects: 72
Study 7862229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin at 0.5 mg/kg
Number of subjects: 72
Study 2658689 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg iv) followed by succinylcholine 20 mg iv
Number of subjects: 22
Study 2658689 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 20 mg iv alone
Number of subjects: 22
Study 30615038 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 1665
Study 30615038 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1665
Study 30615038 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up infarct volume (FIV)
Number of subjects: 1665
Study 27977300 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) program
Number of subjects: 547
Study 27977300 — intervention group
Group type: COMPARATOR
Intervention: Resistive rubber-band running program
Number of subjects: 547
Study 25529832 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1864
Study 25529832 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 1864
Study 23524622 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaya preparation (Caricol®)
Number of subjects: 0
Study 23524622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21518736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anaesthesia
Number of subjects: 128
Study 21518736 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anaesthesia
Number of subjects: 128
Study 21518736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral desaturation
Number of subjects: 128
Study 21518736 — intervention group
Group type: EXPERIMENTAL
Intervention: No cerebral desaturation
Number of subjects: 128
Study 21518736 — intervention group
Group type: EXPERIMENTAL
Intervention: General clinical outcome
Number of subjects: 128
Study 19533753 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 10
Study 19533753 — intervention group
Group type: COMPARATOR
Intervention: Covert placebo (CP)
Number of subjects: 10
Study 19533753 — intervention group
Group type: COMPARATOR
Intervention: Overt placebo (OP)
Number of subjects: 10
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + metronidazole 250 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid)
Number of subjects: 245
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + furazolidone 100 mg 2 tab. bid + tetracycline 250 mg 2 cap. bid)
Number of subjects: 245
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (omeprazole 20 mg bid + bismuth subcitrate 120 mg 2 tab. bid + ciprofloxacin 500 mg bid)
Number of subjects: 245
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (in males)
Number of subjects: 245
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (in males)
Number of subjects: 245
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (in females)
Number of subjects: 245
Study 15795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C (in females)
Number of subjects: 245
Study 10703873 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 10703873 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene (HT)
Number of subjects: 0
Study 8953674 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-streptococci spray treatment for at least 5 days
Number of subjects: 130
Study 8953674 — intervention group
Group type: COMPARATOR
Intervention: placebo spray treatment for at least 5 days
Number of subjects: 130
Study 1773094 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 8
Study 1773094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6755544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 60
Study 6755544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioglicinate
Number of subjects: 60
Study 6755544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioglicinate-Lidocaine mixture
Number of subjects: 60
Study 30877484 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30-60 mg per day for 4 weeks
Number of subjects: 0
Study 30877484 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 75-150 mg per day for 4 weeks
Number of subjects: 0
Study 29037092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (CT)
Number of subjects: 80
Study 29037092 — intervention group
Group type: COMPARATOR
Intervention: Dichotic listening training
Number of subjects: 80
Study 29037092 — intervention group
Group type: COMPARATOR
Intervention: Compensatory strategies
Number of subjects: 80
Study 29037092 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 80
Study 27118109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone
Number of subjects: 97
Study 24790069 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily)
Number of subjects: 80
Study 24790069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23106320 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene clips applied to the breech and tail of lambs
Number of subjects: 32028
Study 20703230 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg per day)
Number of subjects: 87
Study 20703230 — intervention group
Group type: COMPARATOR
Intervention: Imidapril (2.5-10 mg per day) added to valsartan (160 mg per day)
Number of subjects: 87
Study 20703230 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg per day)
Number of subjects: 87
Study 17434727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg b.i.d.
Number of subjects: 22
Study 17434727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16362647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (100 mg)
Number of subjects: 115
Study 16362647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 11939923 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 125
Study 11939923 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 125
Study 9803047 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) oxycodone 30 mg every 12 hr
Number of subjects: 111
Study 9803047 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone 15 mg four times daily
Number of subjects: 111
Study 9803047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR and IR oxycodone
Number of subjects: 111
Study 8919986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dosage method (group I, 33 patients)
Number of subjects: 55
Study 8919986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 micrograms/kg (group II, 8 patients)
Number of subjects: 55
Study 8919986 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg (group III, 12 patients)
Number of subjects: 55
Study 8919986 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 55
Study 2550644 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 10 mg
Number of subjects: 16
Study 2550644 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg
Number of subjects: 16
Study 30692001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic milk model using PTA traits for milk yield, fat, and protein
Number of subjects: 1904
Study 29185253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0
Study 29185253 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 25673441 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (four-drug FDC)
Number of subjects: 38
Study 25673441 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (two-drug FDC)
Number of subjects: 38
Study 25673441 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C (two-drug FDC)
Number of subjects: 38
Study 25673441 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation D (two-drug FDC)
Number of subjects: 38
Study 25673441 — intervention group
Group type: COMPARATOR
Intervention: Reference (free combinations)
Number of subjects: 38
Study 25608545 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Program on Comprehensive Lifestyle Modification
Number of subjects: 68
Study 25608545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 22743352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health literacy and destigmatization condition
Number of subjects: 59
Study 22743352 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 59
Study 22743352 — intervention group
Group type: EXPERIMENTAL
Intervention: Help-seeking list condition
Number of subjects: 59
Study 22743352 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 59
Study 20202537 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with micro-bypass stent implantation
Number of subjects: 0
Study 20202537 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification alone (control group)
Number of subjects: 0
Study 17047022 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 87
Study 17047022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff perception of patients' emotional problems
Number of subjects: 29
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff perception of patients' family problems
Number of subjects: 29
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff perception of patients' coping ability
Number of subjects: 29
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff perception of patients' mental health
Number of subjects: 29
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff assessment of patients' physical symptoms
Number of subjects: 29